Latest Drug repositioning Stories
Chris Klaus Backs Promising New Venture in Intellimedix ATLANTA, Feb.
Paper Addresses Challenges and Explores Opportunities to Stimulate Repurposing of FDA-Approved Drugs for Alzheimer's, Parkinson's and Related Diseases NEW YORK, June 26, 2014 /PRNewswire-USNewswire/
CHARLOTTESVILLE, Virginia and ATHENS, Greece, May 5, 2011 /PRNewswire/ -- Biovista Inc. announced today that it's EU affiliate has been awarded a prestigious grant worth $0.5 million, for research and development in the area of personalized medicine.
CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ -- Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE).
CHARLOTTESVILLE, Virginia, December 16 /PRNewswire/ -- Biovista Inc. today announced that it was awarded the 2009 Top Innovator Presentation Award in Healthcare, at the 2009 New England Venture Summit, held on December 8th at Dedham, MA.
Ore Pharmaceuticals has acquired from Roche the clinical-stage compound tiapamil. The company had previously identified potentially novel therapeutic uses for tiapamil in central nervous system disease and recently filed for patent protection regarding the use of the compound.
Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has acquired from Roche the clinical-stage compound tiapamil.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.